GSE161218
Drug repurposing unveils new combinatorial treatments to treat mutant KRAS lung cancer
We report data on a drug combination with synergistic antitumor effect in KRAS-driven lung cancer. We used RNAseq to characterize the transcriptional changes elicited by each drug in a mutant KRAS lung cancer cell lines (H1792) Overall design: H1792 cell line treated with Trametinib (MEKi) or Lestaurtinib (multikinase FLT3i) for 16 hours